Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 491

The DOI matches its Crossref record; 454 of the 454 references it cites were found in a registry or an index.

G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery

Open access
Zhang, Mingyang, Chen, Ting, Lu, Xun, Lan, Xiaobing, Chen, Ziqiang, Lu, Shaoyong·2024·Signal Transduction and Targeted Therapy

Abstract

G protein-coupled receptors (GPCRs), the largest family of human membrane proteins and an important class of drug targets, play a role in maintaining numerous physiological processes. Agonist or antagonist, orthosteric effects or allosteric effects, and biased signaling or balanced signaling, characterize the complexity of GPCR dynamic features. In this study, we first review the structural advancements, activation mechanisms, and functional diversity of GPCRs. We then focus on GPCR drug discovery by revealing the detailed drug-target interactions and the underlying mechanisms of orthosteric drugs approved by the US Food and Drug Administration in the past five years. Particularly, an up-to-date analysis is performed on available GPCR structures complexed with synthetic small-molecule allosteric modulators to elucidate key receptor-ligand interactions and allosteric mechanisms. Finally, we highlight how the widespread GPCR-druggable allosteric sites can guide structure- or mechanism-based drug design and propose prospects of designing bitopic ligands for the future therapeutic potential of targeting this receptor family.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-024-01803-6

Cites

454 of 454 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 454 references

Research works printed but not linked: 25

  1. Li, D. F. & Caffrey, M. Structure and functional characterization of membrane integral proteins in the lipid cubic phase. J. Mol. Biol. 432, 5104–5123 (2020). · doi:10.1016/j.jmb.2020.02.024
  2. Rubovitch, V., Gafni, M. & Sarne, Y. The mu opioid agonist DAMGO stimulates cAMP production in SK-N-SH cells through a PLC-PKC-Ca++ pathway. Mol. Brain Res. 110, 261–266 (2003). · doi:10.1016/s0169-328x(02)00656-3
  3. Hershberger, P. M. et al. Imidazole-derived agonists for the neurotensin 1 receptor. Bioorg. Med. Chem. Lett. 24, 262–267 (2014). · doi:10.1016/j.bmcl.2013.11.026
  4. Fan, Y. et al. The identification of neurotensin NTS1 receptor partial agonists through a ligand-based virtual screening approach. Bioorg. Med. Chem. Lett. 18, 5789–5791 (2008). · doi:10.1016/j.bmcl.2008.09.075
  5. Yang, X. et al. Discovery of small molecule agonist of Gonadotropin-Releasing Hormone Receptor (GnRH1R). J. Chem. Inf. Model. 62, 5009–5022 (2022). · doi:10.1021/acs.jcim.2c00639
  6. Barman Balfour, J. A. & Scott, L. J. Cinacalcet hydrochloride. Drugs 65, 271–281 (2005). · doi:10.2165/00003495-200565020-00007
  7. Xu, X. Y. et al. Constrained catecholamines gain β2AR selectivity through allosteric effects on pocket dynamics. Nat. Commun. 14, 2138–2150 (2023). · doi:10.1038/s41467-023-37808-y
  8. Akizawa, T. et al. Evocalcet: A new oral calcimimetic for dialysis patients with secondary Hyperparathyroidism. Ther. Apher. Dial. 24, 248–257 (2020). · doi:10.1111/1744-9987.13434
  9. Liu, F. et al. Structure-based discovery of positive allosteric modulators for the calcium sensing receptor. bioRxiv 573448 (2023).
  10. Mane, N., Jimenez-Sabado, V. & Jimenez, M. BPTU, an allosteric antagonist of P2Y1 receptor, blocks nerve mediated inhibitory neuromuscular responses in the gastrointestinal tract of rodents. Neuropharmacology 110, 376–385 (2016). · doi:10.1016/j.neuropharm.2016.07.033
  11. Zhuang, Y. W. et al. Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor. Cell Res 31, 593–596 (2021). · doi:10.1038/s41422-021-00482-0
  12. Sibley, D. R., Luderman, K. D., Free, R. B. & Shi, L. Novel Cryo-EM structures of the D1 dopamine receptor unlock its therapeutic potential. Signal Transduct. Target. Ther. 6, 205 (2021). · doi:10.1038/s41392-021-00630-3
  13. Milanos, L. et al. Discovery and characterization of biased allosteric agonists of the chemokine Receptor CXCR3. J. Med. Chem. 59, 2222–2243 (2016). · doi:10.1021/acs.jmedchem.5b01965
  14. Lee, D. F., Geron, M. & Scherrer, G. A modulator-bound GPCR structure enables allosteric non-opioid analgesia. Nat. Struct. Mol. Biol. 28, 871–872 (2021). · doi:10.1038/s41594-021-00681-8
  15. Cong, X. J. et al. Allosteric modulation mechanism of the mGIuR(5) Transmembrane domain. J. Chem. Inf. Model. 59, 2871–2878 (2019). · doi:10.1021/acs.jcim.9b00045
  16. Kumar, K. K. et al. Step-wise activation of a Family C GPCR. Biorxiv. https://doi.org/10.1101/2023.08.29.555158 (2023). · doi:10.1101/2023.08.29.555158
  17. Nishimura, Y. et al. Lead optimization and avoidance of reactive metabolite leading to PCO371, a potent, selective, and orally available human parathyroid hormone receptor 1 (hPTHR1) agonist. J. Med. Chem. 63, 5089–5099 (2020). · doi:10.1021/acs.jmedchem.9b01743
  18. Xiao, H., Sun, Q. & Sun, Q. A promising small molecule binding pocket in class B GPCRs: expanding potential for drug development. Signal Transduct. Target. Ther. 8, 313 (2023). · doi:10.1038/s41392-023-01598-y
  19. Monnier, C. et al. Trans-activation between 7TM domains: implication in heterodimeric GABAB receptor activation. EMBO J. 30, 32–42 (2011). · doi:10.1038/emboj.2010.270
  20. Powers, A. S. et al. Structural basis of efficacy-driven ligand selectivity at GPCRs (Feb, 10.1038/s41589-022-01247-5, 2023). Nat. Chem. Biol. 19, 529–529 (2023). · doi:10.1038/s41589-023-01297-3
  21. Liu, H. T. et al. Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists. Proc. Natl Acad. Sci. USA 115, 12046–12050 (2018). · doi:10.1073/pnas.1813988115
  22. Wang, X. D. et al. Intermediate-state-trapped mutants pinpoint G protein-coupled receptor conformational allostery. Nat. Commun. 14, 1325–1334 (2023). · doi:10.1038/s41467-023-36971-6
  23. Aurelio, L. et al. A structure-activity relationship study of bitopic N6-substituted adenosine derivatives as biased Adenosine A1 receptor agonists. J. Med. Chem. 61, 2087–2103 (2018). · doi:10.1021/acs.jmedchem.8b00047
  24. Wang, X. W. et al. Structural insights into dimerization and activation of the mGlu2-mGlu3 and mGlu2-mGlu4 heterodimers. Cell Res 33, 762–774 (2023). · doi:10.1038/s41422-023-00830-2
  25. Li, F. H. et al. Molecular recognition and activation mechanism of short-chain fatty acid receptors FFAR2/3. Cell Res. https://doi.org/10.1038/s41422-023-00914-z (2024). · doi:10.1038/s41422-023-00914-z

Cited by

See all 491

Metadata

Authors
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S.
Venue
Signal Transduction and Targeted Therapy
Published
2024-04-10
Volume
9
Issue
1
Pages
88-88
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4394623467
Cited by
491
References
454
FWCI
56.93
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • National Natural Science Foundation of China (22077082)
  • the Shanghai Frontiers Science Center of Cellular Homeostasis and the Human Diseases, and the Innovative Research Team of High-Level Local Universities in Shanghai

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery. https://app.cochat.ai/papers/10.1038/s41392-024-01803-6
The paper
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024). G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-024-01803-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.